| First Author | Srivastava J | Year | 2025 |
| Journal | Cancer Res | Volume | 85 |
| Issue | 12 | Pages | 2268-2287 |
| PubMed ID | 40287947 | Mgi Jnum | J:386354 |
| Mgi Id | MGI:8214759 | Doi | 10.1158/0008-5472.CAN-24-0693 |
| Citation | Srivastava J, et al. (2025) Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Res 85(12):2268-2287 |
| abstractText | Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide-induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS-mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS-mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2alpha, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8+ T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS-mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS-mutant melanoma subtype. SIGNIFICANCE: Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS-mutant melanomas to existing targeted therapies while enhancing antitumor immunity. |
